HK1049830A1 - 用於治療惡性腫瘤的藥物 - Google Patents

用於治療惡性腫瘤的藥物

Info

Publication number
HK1049830A1
HK1049830A1 HK03100644.7A HK03100644A HK1049830A1 HK 1049830 A1 HK1049830 A1 HK 1049830A1 HK 03100644 A HK03100644 A HK 03100644A HK 1049830 A1 HK1049830 A1 HK 1049830A1
Authority
HK
Hong Kong
Prior art keywords
treatment
drugs
malignant tumours
compounds
formula
Prior art date
Application number
HK03100644.7A
Other languages
English (en)
Inventor
Hedlund Gunnar
Jansson Karl
Jonsson Stig
Bjork Anders
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of HK1049830A1 publication Critical patent/HK1049830A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
HK03100644.7A 1999-10-25 2003-01-24 用於治療惡性腫瘤的藥物 HK1049830A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (1)

Publication Number Publication Date
HK1049830A1 true HK1049830A1 (zh) 2003-05-30

Family

ID=27484521

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100644.7A HK1049830A1 (zh) 1999-10-25 2003-01-24 用於治療惡性腫瘤的藥物

Country Status (21)

Country Link
EP (1) EP1224172B1 (zh)
JP (1) JP3950337B2 (zh)
KR (2) KR100674160B1 (zh)
AT (1) ATE358668T1 (zh)
AU (1) AU775057B2 (zh)
CA (1) CA2386775C (zh)
CZ (1) CZ298534B6 (zh)
DE (1) DE60034240T2 (zh)
DK (1) DK1224172T3 (zh)
EE (1) EE200200207A (zh)
ES (1) ES2280258T3 (zh)
HK (1) HK1049830A1 (zh)
HR (1) HRP20020353A2 (zh)
HU (1) HU229072B1 (zh)
IL (2) IL148782A0 (zh)
IS (1) IS2750B (zh)
NO (1) NO323320B1 (zh)
NZ (1) NZ518296A (zh)
SE (1) SE0002320D0 (zh)
UA (1) UA73748C2 (zh)
WO (1) WO2001030758A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2810655C (en) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
BRPI0617477A2 (pt) 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
EP3708564A1 (en) 2005-12-28 2020-09-16 Vertex Pharmaceuticals Incorporated A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2035001B1 (en) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
BRPI0913518A2 (pt) 2008-09-03 2016-07-26 Teva Pharma composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune
KR101852173B1 (ko) 2009-03-20 2018-04-27 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
AU2011314411B2 (en) * 2010-10-14 2014-06-12 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AhR activators.
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
BR112015010193A2 (pt) * 2012-11-07 2017-07-11 Teva Pharma sais de amina de laquinimod
KR20150143499A (ko) 2013-03-14 2015-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법
AU2015316824B2 (en) 2014-09-23 2020-10-29 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
KR102525805B1 (ko) * 2014-11-19 2023-04-25 액티브 바이오테크 에이비 백혈병 치료용 퀴놀린 카르복사미드
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
EP4114368A1 (en) 2020-03-03 2023-01-11 Active Biotech AB Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
US20240091215A1 (en) 2021-01-18 2024-03-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
IL308542A (en) 2021-05-25 2024-01-01 Active Biotech Ab Multiparticles of tesquinimod and their use
WO2023275248A1 (en) 2021-07-02 2023-01-05 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
WO2023039275A1 (en) * 2021-09-13 2023-03-16 Eli Lilly And Company Ahr agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
IL148782A (en) 2007-05-15
IL148782A0 (en) 2002-09-12
EE200200207A (et) 2003-06-16
IS6329A (is) 2002-04-02
CZ298534B6 (cs) 2007-10-31
CA2386775A1 (en) 2001-05-03
DE60034240T2 (de) 2007-12-20
EP1224172B1 (en) 2007-04-04
KR100597938B1 (ko) 2006-07-06
AU775057B2 (en) 2004-07-15
HRP20020353A2 (en) 2005-10-31
HU229072B1 (en) 2013-07-29
JP2003512454A (ja) 2003-04-02
WO2001030758A1 (en) 2001-05-03
IS2750B (is) 2011-08-15
HUP0203238A2 (hu) 2003-01-28
NO323320B1 (no) 2007-03-12
KR100674160B1 (ko) 2007-01-24
HUP0203238A3 (en) 2003-05-28
DK1224172T3 (da) 2007-08-13
ES2280258T3 (es) 2007-09-16
EP1224172A1 (en) 2002-07-24
CA2386775C (en) 2004-07-13
UA73748C2 (en) 2005-09-15
DE60034240D1 (de) 2007-05-16
SE0002320D0 (sv) 2000-06-21
ATE358668T1 (de) 2007-04-15
CZ20021293A3 (cs) 2002-07-17
NZ518296A (en) 2003-06-30
NO20021932L (no) 2002-06-21
KR20060054496A (ko) 2006-05-22
JP3950337B2 (ja) 2007-08-01
NO20021932D0 (no) 2002-04-24
KR20020043646A (ko) 2002-06-10
AU1185101A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
YU23202A (sh) Lekovi za tretman malignih tumora
IL148782A0 (en) Drugs for the treatment of malignant tumours
PL367682A1 (en) Dolastatin 10 derivatives
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
SE9904505D0 (sv) Novel compounds
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
MY146279A (en) Compounds affecting glucokinase
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
MY128924A (en) Novel compounds
PL1727817T3 (pl) Pochodne azabicyklooktan-3-onu i ich zastosowanie
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
GB0109122D0 (en) Novel compounds
IL147149A0 (en) Novel diphenyl-piperidine derivate
PL342614A1 (en) Anticarcinogenic drugs
JO2390B1 (en) Diphenylcarboxamides act as lipid-lowering agents
AU2002352708A1 (en) Cytotoxic agents
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
TW200634002A (en) Chemical compounds
GB9907571D0 (en) Compounds
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
NO20030420L (no) Medikament for immunoterapi av maligne tumorer
SE0004827D0 (sv) Therapeutic compounds
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents